Dr. Farid Menaa (Bsc. BioEngineering ; Bsc. Biology and Physiology ; Msc. Genetics ; Master Gerontology/Geriatrics ; PhD Radiation Oncology/Gerontology (Paris, France, 2003) ; three international post-doctoral terms in Oncology, Dermatology, Stem cells, Hematology, Genomics ; MBA Entrepreneurship and MD candidate), is an experienced and skilled inter- and multi-disciplinary professional. During his career, Dr. Menaa followed complementary formations in Marine Biology (Caen, France), Pharmacy (Liege, Belgium), Biochemistry, Chemistry and Biophysics (California, USA), Business Development and Management (USA and Brazil). During his ongoing career, Dr. Menaa has mainly contributed to the identification and function of new human genes modulated by radiation ; Discovered a new signaling pathway after DNA damage ; Pointed out the link between the presence of stem cells, some of their genetic mutations, and the patient’s diagnosis and prognostic ; Identified genomic alterations in adult sickle cell anemia patients with stroke ; Developed new phytotherapeutic formulations against skin conditions ; Demonstrated the importance of various natural medicines in the prevention and/or treatment of diverse inflammatory-state and non-communicable diseases (NCDs) ; Contributed to the development and characterization of new nanomaterials ; Developped personalized translational medical strategies to diagnose and treat better and faster chronic pathologies. In 2009, Dr. Menaa was named Chief Scientific Officer (CSO) and R&D&I Executive Vice-Pressident (EVP) for Fluorotronics, Inc, CA, USA, the leading company in Fluorine-Carbon Spectroscopy. Dr. Menaa co-developped and applied this innovative green technology to Nanomedicine, Medicinal Chemistry, Nanotechnology, Oncology, Pharmaceutical and Life Sciences. Dr. Menaa is currently Chief Editor of Journal of Nanomedicine and Nanotechnology (http://www.omicsonline.org/editorialboard-nanomedicine-nanotechnology-open-access.php), among his other involvements for the advancement of Medicine, Sciences and Technology. Dr. Menaa is the member of the technical/scientific committee of a large number of international scientific events, in particular he successfully organized the “Target Meeting´s 1st World Nanomedicine and Nanobiotechnology Online Conference” (http://www.targetmeeting.com; 2013). Dr. Menaa is also member of several prestigious medical and scientific organizations (e.g. AACR, AAAS, ASCB, IRSCC, SPIE, RSC, ACS, ASH, ASHG, AAPS), and the editor, guest editor and reviewer of a large number of esteemed journals worldwide (>80 in Sciences , Medicine, Technology and Business Administration). Dr. Menaa has authored or co-authored more than 100 articles (including research and review articles, books, book chapters, textbooks, proceedings, pending patents) and has participated to over 200 scientific international events. Overall, the holistic concept of Dr. Menaa led him to contribute for various clinical and R&D&I projects at the interface of Oncology, Nutrition/Micronutrition, Aging/Anti-Aging, OMICS (mainly Genomics) and Nanotechnology, in order to prevent, implement early diagnosis, and develop efficient and safer therapeutic options, in particular to improve the outcome of cancer patients, stroke patients and delay the aging process while improving their life quality.
Nanomedicine,Nanobiotechnology,Nanotheranostics; Oncology, Gerontology, Dermatology, Stem Cells, Emerging Green Technologies, Personalized Medicine; Translational Medicine; Integrative Biomedicine; Innovation & Quality, Professorship, Entrepreneurship, Business Development/Management, Marketing.